Showing results (281-290 of 379) with videos related to

Sort By:
Pageof 38
Wiener Klinische Wochenschrift|December 21, 1990
[Pharmacokinetic aspects of dosage increase of recombinant interferon alpha-2B in patients following intraperitoneal and intra-arterial application]J Schüller, M Wirth, C Bosse, et al.
General Dentistry|January 3, 2022
Efficacy of various decontamination methods and sterilization on contaminated and inoculated diamond-coated bursNicole M Wirth, Lori E Henrichs, Daniel Savett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 1, 1996
Heterogeneity of cerebral hemodynamics and metabolism in carotid artery diseaseD B Duncan, G R Fink, M Wirth, et al.
Seminars in Oncology|April 1, 1992
Pharmacokinetic aspects of interferon alfa-2b after intrahepatic or intraperitoneal administrationJ Schüller, M J Czejka, G Schernthaner, et al.
Neuroreport|April 7, 2007
Central ghrelin induces feeding driven by energy needs not by rewardEric M Bomberg, Martha K Grace, Michelle M Wirth, et al.
European Urology|November 1, 2005
Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancerP-A Abrahamsson, J Anderson, L Boccon-Gibod, et al.
FEBS Letters|February 24, 1997
Ribonuclease T1 has different dimensions in the thermally and chemically denatured states: a dynamic light scattering studyK Gast, D Zirwer, H Damaschun, et al.
The Journal of Prevention of Alzheimer'S Disease|February 7, 2018
Effects of Omega-3 Fatty Acids on Resting Cerebral Perfusion in Patients with Mild Cognitive Impairment: A Randomized Controlled TrialC Schwarz, M Wirth, L Gerischer, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|August 15, 2012
Lectin bioconjugates trigger urothelial cytoinvasion--a glycotargeted approach for improved intravesical drug deliveryL Neutsch, B Eggenreich, E Herwig, et al.
Human Gene Therapy|February 18, 1999
Gene therapy--phase I trial for primary untreated head and neck squamous cell cancer (HNSCC) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/CholB Wollenberg, Kastenbauer, H Mundl, et al.
Pageof 38